Price$13.45+7.18 (+114.60%)
2026-03-192026-06-23
News · 26 weeks80+220%
2025-12-282026-06-21
Mix6290d
- Insider31(50%)
- Other13(21%)
- SEC Filings13(21%)
- Earnings3(5%)
- Analyst1(2%)
- M&A1(2%)
Latest news
25 items- PROrganon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVAThe launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS® (denosumab injection) 60 mg/1 mL and TUZEMTY® (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, are now available in Canada for all indications of reference products. Used across several indications, denosumab products treat osteoporosis and bone events associated with cancer by helping to strengthen bones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623760250/en/ "The approvals represent a
- PROrganon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine DeviceThis transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA®, a hormone-free, copper intrauterine device (IUD). Please see our prior announcement for a summary of the transaction terms. Approved by the US Food and Drug Administration (FDA) on February 24, 2025, MIUDELLA is the first hormone-free copper IUD to be introduced in the US in over 40 years. Indicated for
- PROrganon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in CanadaThe amended agreement deepens Organon and Samsung Bioepis's collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology. To be launched in Canada in 2026 Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA®, Samsung Bioepis's biosimilar referencing STELARA® (ustekinumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618749080/en/ PYZCHIVA® is indicated for the tre
- SECSEC Form DEFM14A filed by Organon & Co.DEFM14A - Organon & Co. (0001821825) (Filer)
- INSIDERSEC Form 4 filed by Director Sharp Shalini4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Sequeira Ramona4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Patton Cynthia M4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Ozuah Philip4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Leone Deborah R4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Lazarus Rochelle B4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Gayle Helene D4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Ezekowitz Alan4 - Organon & Co. (0001821825) (Issuer)
- INSIDERSEC Form 4 filed by Director Essner Robert4 - Organon & Co. (0001821825) (Issuer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- PROrganon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasiv
- SECSEC Form PREM14A filed by Organon & Co.PREM14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form SD filed by Organon & Co.SD - Organon & Co. (0001821825) (Filer)
- PROrganon to Present New Research on Access and Value at ISPOR 2026New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women's health and general medicines portfolio Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women's health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect O
- INSIDERAmendment: SVP and Corporate Controller Holzbaur Lynette sold $353,080 worth of shares (26,448 units at $13.35) and acquired 46 shares, closing all direct ownership in the company (SEC Form 4)4/A - Organon & Co. (0001821825) (Issuer)
- INSIDERSVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)4 - Organon & Co. (0001821825) (Issuer)
- SECSEC Form 10-Q filed by Organon & Co.10-Q - Organon & Co. (0001821825) (Filer)
- SECSEC Form SCHEDULE 13G filed by Organon & Co.SCHEDULE 13G - Organon & Co. (0001821825) (Subject)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECSEC Form DEFA14A filed by Organon & Co.DEFA14A - Organon & Co. (0001821825) (Filer)
- SECOrganon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Organon & Co. (0001821825) (Filer)
OGN FAQ
7 questionsWhat does Organon & Co. do?
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a...Where does OGN stock trade?
Organon & Co. (OGN) is listed on NYSE.What sector and industry is OGN in?
Organon & Co. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Organon & Co. go public?
Organon & Co. (OGN) completed its IPO in 2021.What are analysts saying about OGN?
Organon & Co. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $1400.00 price target on 2026-04-28.What companies are similar to OGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OGN side-by-side with any of them on Quantisnow.How can I track OGN on Quantisnow?
Quantisnow aggregates Organon & Co.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OGN to receive live email and push alerts on every new disclosure.